Searchable abstracts of presentations at key conferences in endocrinology

ea0091cb27 | Additional Cases | SFEEU2023

Iatrogenic Graves’ disease - A case of severe Graves’ disease and Graves’ orbitopathy occuring after radioiodine therapy for toxic nodular goitre

Olaremi Japhet

Radio-active iodine (RAI) therapy is effective in managing hyperthyroidism due to solitary toxic thyroid nodule, in which 90% efficacy is observed. The most common side effects of RAI include hypothyroidism, transient neck pain and dry mouth and eyes. Occasionally, transient worsening of hyperthyroidism or the development of new-onset Graves’ orbitopathy (GO) has been reported in patients with GD after RAI therapy. However, there is scant literature regarding the risk of ...

ea0094op4.3 | Thyroid | SFEBES2023

Prevalence, predictors and rhythm outcome of Atrial fibrillation (AF) in patients with Graves hyperthyroidism

Olaremi Japhet , Razvi Salman

Background: Graves disease is an autonomous condition characterised by interaction of the TSH receptor with autoantibody(TRAb). It is well recognised that atrial fibrillation (AF) is a consequence of hyperthyroidism but the prevalence, predictors and outcomes of AF in patients with Graves hyperthyroidism is not completely known.Method: We analysed a prospective database of Graves disease patients over a 16 year period fr...

ea0090p697 | Pituitary and Neuroendocrinology | ECE2023

Transphenoidal surgery for sellar and suprasellar lesions: a prospective analysis of factors affecting inpatient length of stay

Ali Mudassir , Olaremi Japhet , Ali Rashid Razan , Mamoojee Yaasir

Background: The recent Get It Right First Time (GIRT) report suggests short stay pathways should be aimed for in pituitary surgery in England, with 1–2 days being realistic. We prospectively audited the length of stay (LOS) for patients undergoing transsphenoidal surgery (TSS) for sellar and suprasellar lesions at the Royal Victoria infirmary hospital (RVI) over a 2-year period, from October 2019.Methods: Data was prospectively collected for each pa...

ea0086p189 | Bone and Calcium | SFEBES2022

Denosumab induced recurrent, prolonged and life threatening hypocalcaemia

Tahir Chohan Muhammad , Olaremi Japhet , So Pye Dr , Sony Anthony Dr

Introduction: Denosumab, a human monoclonal antibody used in osteoporosis and second line treatment option for hypercalcaemia, can cause profound hypocalcaemia especially in Vitamin-D depleted and cancer patients.Case history: 56 years female, with diabetes, hypertension on metformin, empagliflozin, amlodipine and ramipril, presented with 3 months history of backache, no red flag signs, clinically and hemodynamically stable except mild confusion and spin...